Header Logo

Connection

Christopher Goetz to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Parkinson Disease.
Christopher Goetz
Connection Strength
21.797
Parkinson Disease
  1. Reply to: Comment on "Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice". Mov Disord. 2023 08; 38(8):1564.
    View in: PubMed
    Score: 0.469
  2. It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum. Mov Disord. 2023 02; 38(2):342-347.
    View in: PubMed
    Score: 0.449
  3. The plight of loneliness in Parkinson's disease: New opportunities. Parkinsonism Relat Disord. 2022 Dec; 105:145-148.
    View in: PubMed
    Score: 0.445
  4. Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 08; 92(2):345-346.
    View in: PubMed
    Score: 0.435
  5. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
    View in: PubMed
    Score: 0.423
  6. Apathy in Parkinson disease: Why we should care. Neurology. 2020 11 17; 95(20):893-894.
    View in: PubMed
    Score: 0.386
  7. The Evolution-Driven Signature of Parkinson's Disease. Trends Neurosci. 2020 07; 43(7):475-492.
    View in: PubMed
    Score: 0.377
  8. Parkinson's disease: Is it a consequence of human brain evolution? Mov Disord. 2019 04; 34(4):453-459.
    View in: PubMed
    Score: 0.344
  9. What influences placebo and nocebo responses in Parkinson's disease? Mov Disord. 2018 08; 33(8):1204-1212.
    View in: PubMed
    Score: 0.333
  10. Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years? Mov Disord. 2017 12; 32(12):1651-1652.
    View in: PubMed
    Score: 0.316
  11. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. Mov Disord. 2016 12; 31(12):1865-1873.
    View in: PubMed
    Score: 0.294
  12. Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):11-22.
    View in: PubMed
    Score: 0.276
  13. Preface. Mov Disord. 2015 Sep 15; 30(11):1441.
    View in: PubMed
    Score: 0.271
  14. Handling missing values in the MDS-UPDRS. Mov Disord. 2015 Oct; 30(12):1632-8.
    View in: PubMed
    Score: 0.261
  15. Initial management of Parkinson's disease. BMJ. 2014 Dec 19; 349:g6258.
    View in: PubMed
    Score: 0.258
  16. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9.
    View in: PubMed
    Score: 0.252
  17. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Mov Disord. 2014 Sep; 29(10):1252-7.
    View in: PubMed
    Score: 0.248
  18. Are patients with Parkinson's disease blind to blindsight? Brain. 2014 Jun; 137(Pt 6):1838-49.
    View in: PubMed
    Score: 0.247
  19. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar; 137(Pt 3):849-59.
    View in: PubMed
    Score: 0.243
  20. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov Disord. 2014 Jan; 29(1):115-7.
    View in: PubMed
    Score: 0.234
  21. The Parkinson's disease multidisciplinary package. Mov Disord. 2013 May; 28(5):565.
    View in: PubMed
    Score: 0.228
  22. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord. 2012 Sep 01; 27(10):1239-42.
    View in: PubMed
    Score: 0.219
  23. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan; 260(1):228-36.
    View in: PubMed
    Score: 0.219
  24. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012 Aug; 27(9):1129-36.
    View in: PubMed
    Score: 0.218
  25. Tai chi for patients with Parkinson's disease. N Engl J Med. 2012 05 03; 366(18):1737-8; author reply 1738.
    View in: PubMed
    Score: 0.215
  26. Vibration therapy for Parkinson's disease: Charcot's studies revisited. J Parkinsons Dis. 2012; 2(1):23-7.
    View in: PubMed
    Score: 0.210
  27. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord. 2012 Feb; 27(2):248-53.
    View in: PubMed
    Score: 0.209
  28. Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011 Dec; 26(14):2556-9.
    View in: PubMed
    Score: 0.206
  29. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a008862.
    View in: PubMed
    Score: 0.206
  30. Wearing-off scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Oct; 26(12):2169-75.
    View in: PubMed
    Score: 0.204
  31. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct; 26(12):2196-200.
    View in: PubMed
    Score: 0.204
  32. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother. 2011 Sep; 12(13):2009-24.
    View in: PubMed
    Score: 0.202
  33. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.200
  34. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15; 25(16):2704-16.
    View in: PubMed
    Score: 0.196
  35. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16; 75(20):1773-9.
    View in: PubMed
    Score: 0.194
  36. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
    View in: PubMed
    Score: 0.192
  37. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010 Jul 15; 25(9):1190-4.
    View in: PubMed
    Score: 0.190
  38. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S104-9.
    View in: PubMed
    Score: 0.183
  39. Jean-Martin Charcot and his vibratory chair for Parkinson disease. Neurology. 2009 Aug 11; 73(6):475-8.
    View in: PubMed
    Score: 0.178
  40. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009 Jun; 5(6):331-42.
    View in: PubMed
    Score: 0.176
  41. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord. 2009 Apr 15; 24(5):635-46.
    View in: PubMed
    Score: 0.174
  42. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008 Dec; 64 Suppl 2:S81-92.
    View in: PubMed
    Score: 0.170
  43. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.169
  44. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2004-14.
    View in: PubMed
    Score: 0.169
  45. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2015-25.
    View in: PubMed
    Score: 0.169
  46. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology. 2008 Aug 26; 71(9):677-84.
    View in: PubMed
    Score: 0.167
  47. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
    View in: PubMed
    Score: 0.166
  48. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.166
  49. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.164
  50. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008 Apr 15; 23(5):700-7.
    View in: PubMed
    Score: 0.163
  51. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View in: PubMed
    Score: 0.163
  52. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15; 23(4):484-500.
    View in: PubMed
    Score: 0.162
  53. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15; 22(8):1061-8.
    View in: PubMed
    Score: 0.153
  54. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15; 22(8):1077-92.
    View in: PubMed
    Score: 0.153
  55. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15; 22(2):179-86.
    View in: PubMed
    Score: 0.149
  56. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.149
  57. Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations. BMC Med Res Methodol. 2006 Jun 13; 6:26.
    View in: PubMed
    Score: 0.143
  58. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.143
  59. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.142
  60. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.140
  61. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May; 20(5):523-39.
    View in: PubMed
    Score: 0.132
  62. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.130
  63. Movement disorders: understanding clinical trials. Lancet Neurol. 2005 Jan; 4(1):5-6.
    View in: PubMed
    Score: 0.129
  64. Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord. 2004 Dec; 19(12):1453-6.
    View in: PubMed
    Score: 0.129
  65. Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
    View in: PubMed
    Score: 0.129
  66. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004 Sep; 19(9):1020-8.
    View in: PubMed
    Score: 0.127
  67. Re: UPDRS: Status and recommendations. Mov Disord. 2004 May; 19(5):605.
    View in: PubMed
    Score: 0.124
  68. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord. 2003 Dec; 18(12):1455-8.
    View in: PubMed
    Score: 0.120
  69. Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
    View in: PubMed
    Score: 0.119
  70. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1146-9.
    View in: PubMed
    Score: 0.119
  71. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord. 2003 Jul; 18(7):831-2.
    View in: PubMed
    Score: 0.117
  72. Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice. Mov Disord. 2023 07; 38(7):1363-1364.
    View in: PubMed
    Score: 0.115
  73. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.115
  74. An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. Nat Commun. 2023 02 18; 14(1):926.
    View in: PubMed
    Score: 0.114
  75. Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. Mov Disord. 2023 04; 38(4):688-692.
    View in: PubMed
    Score: 0.113
  76. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings. Mov Disord. 2023 03; 38(3):453-463.
    View in: PubMed
    Score: 0.113
  77. Treatment of advanced Parkinson's disease: an evidence-based analysis. Adv Neurol. 2003; 91:213-28.
    View in: PubMed
    Score: 0.113
  78. Jean-Martin Charcot and the aging brain. Arch Neurol. 2002 Nov; 59(11):1821-4.
    View in: PubMed
    Score: 0.111
  79. Intestinal microbiota and neuroinflammation in Parkinson's disease: At the helm of the gut-brain axis. Int Rev Neurobiol. 2022; 167:81-99.
    View in: PubMed
    Score: 0.110
  80. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
    View in: PubMed
    Score: 0.109
  81. Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. Mov Disord. 2022 09; 37(9):1904-1914.
    View in: PubMed
    Score: 0.109
  82. Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. Mov Disord. 2022 08; 37(8):1749-1755.
    View in: PubMed
    Score: 0.109
  83. Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status. Neurobiol Dis. 2022 08; 170:105780.
    View in: PubMed
    Score: 0.108
  84. Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. Curr Neurol Neurosci Rep. 2022 07; 22(7):335-342.
    View in: PubMed
    Score: 0.108
  85. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
    View in: PubMed
    Score: 0.106
  86. Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Mov Disord. 2022 04; 37(4):826-841.
    View in: PubMed
    Score: 0.106
  87. Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocol. JBI Evid Synth. 2022 01 01; 20(1):260-269.
    View in: PubMed
    Score: 0.105
  88. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
    View in: PubMed
    Score: 0.103
  89. Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. Mov Disord. 2021 12; 36(12):2853-2861.
    View in: PubMed
    Score: 0.102
  90. Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). Neurol Neurochir Pol. 2021; 55(2):186-194.
    View in: PubMed
    Score: 0.099
  91. In Support of Electronic Versions of Movement Disorder Society Rating Scales. Mov Disord. 2021 01; 36(1):270-271.
    View in: PubMed
    Score: 0.098
  92. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel? J Parkinsons Dis. 2021; 11(1):3-8.
    View in: PubMed
    Score: 0.098
  93. Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. Neuroepidemiology. 2020; 54(4):356-362.
    View in: PubMed
    Score: 0.094
  94. Item Response Theory Analysis of the MDS-UPDRS Motor Examination: Tremor vs. Nontremor Items. Mov Disord. 2020 09; 35(9):1587-1595.
    View in: PubMed
    Score: 0.094
  95. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338.
    View in: PubMed
    Score: 0.090
  96. Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. Parkinsonism Relat Disord. 2019 10; 67:113-116.
    View in: PubMed
    Score: 0.089
  97. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Mov Disord. 2019 06; 34(6):791-798.
    View in: PubMed
    Score: 0.088
  98. The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. Mov Disord. 2019 05; 34(5):676-681.
    View in: PubMed
    Score: 0.087
  99. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018 10; 33(10):1601-1608.
    View in: PubMed
    Score: 0.083
  100. Movement disorder society criteria for clinically established early Parkinson's disease. Mov Disord. 2018 10; 33(10):1643-1646.
    View in: PubMed
    Score: 0.083
  101. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018 07; 52:83-89.
    View in: PubMed
    Score: 0.081
  102. Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Mov Disord. 2018 03; 33(3):499-500.
    View in: PubMed
    Score: 0.080
  103. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord. 2018 02; 33(2):208-218.
    View in: PubMed
    Score: 0.079
  104. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec; 45:7-12.
    View in: PubMed
    Score: 0.078
  105. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
    View in: PubMed
    Score: 0.077
  106. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.074
  107. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation. Mov Disord. 2017 02; 32(2):274-277.
    View in: PubMed
    Score: 0.074
  108. Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. Mov Disord. 2016 10; 31(10):1455-1465.
    View in: PubMed
    Score: 0.073
  109. Abolishing the 1-year rule: How much evidence will be enough? Mov Disord. 2016 11; 31(11):1623-1627.
    View in: PubMed
    Score: 0.073
  110. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
    View in: PubMed
    Score: 0.071
  111. The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 2016 05; 15(6):546-8.
    View in: PubMed
    Score: 0.071
  112. Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. Mov Disord. 2016 09; 31(9):1342-55.
    View in: PubMed
    Score: 0.070
  113. Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. Mov Disord. 2016 05; 31(5):625-31.
    View in: PubMed
    Score: 0.070
  114. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.067
  115. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord. 2015 Mar; 30(3):402-6.
    View in: PubMed
    Score: 0.064
  116. The past, present, and future of telemedicine for Parkinson's disease. Mov Disord. 2014 Jun; 29(7):871-83.
    View in: PubMed
    Score: 0.062
  117. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord. 2014 Apr; 29(4):454-62.
    View in: PubMed
    Score: 0.061
  118. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
    View in: PubMed
    Score: 0.061
  119. Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example. J Parkinsons Dis. 2014; 4(3):395-404.
    View in: PubMed
    Score: 0.060
  120. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013 Dec; 28(14):1972-9.
    View in: PubMed
    Score: 0.059
  121. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6.
    View in: PubMed
    Score: 0.059
  122. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord. 2014 Feb; 29(2):169-76.
    View in: PubMed
    Score: 0.058
  123. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
    View in: PubMed
    Score: 0.058
  124. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord. 2013 Sep; 19(9):806-11.
    View in: PubMed
    Score: 0.058
  125. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.058
  126. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One. 2013; 8(3):e58403.
    View in: PubMed
    Score: 0.057
  127. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
    View in: PubMed
    Score: 0.057
  128. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
    View in: PubMed
    Score: 0.057
  129. Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci. 2013 May; 34(5):683-7.
    View in: PubMed
    Score: 0.054
  130. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord. 2012 May; 27(6):727-34.
    View in: PubMed
    Score: 0.053
  131. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2012 Mar; 18(3):230-3.
    View in: PubMed
    Score: 0.052
  132. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S2-41.
    View in: PubMed
    Score: 0.052
  133. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S42-80.
    View in: PubMed
    Score: 0.052
  134. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012 Jan; 27(1):79-83.
    View in: PubMed
    Score: 0.051
  135. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Nov; 26(13):2371-80.
    View in: PubMed
    Score: 0.051
  136. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011 Sep; 26(11):1985-92.
    View in: PubMed
    Score: 0.050
  137. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011 May; 10(5):377-93.
    View in: PubMed
    Score: 0.050
  138. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010 Aug; 67(8):996-1001.
    View in: PubMed
    Score: 0.048
  139. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Jul 15; 25(9):1131-42.
    View in: PubMed
    Score: 0.048
  140. Shaking up the Salpetriere: Jean-Martin Charcot and mercury-induced tremor. Neurology. 2010 May 25; 74(21):1739-42.
    View in: PubMed
    Score: 0.047
  141. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010 Jun; 16(6):653-61.
    View in: PubMed
    Score: 0.047
  142. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):805-22.
    View in: PubMed
    Score: 0.047
  143. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S38-41.
    View in: PubMed
    Score: 0.046
  144. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
    View in: PubMed
    Score: 0.045
  145. Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
    View in: PubMed
    Score: 0.045
  146. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
    View in: PubMed
    Score: 0.044
  147. Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord. 2009 Mar 15; 24(4):551-6.
    View in: PubMed
    Score: 0.043
  148. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.043
  149. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008 Dec 15; 23(16):2398-403.
    View in: PubMed
    Score: 0.043
  150. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
    View in: PubMed
    Score: 0.041
  151. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007 Dec; 22(16):2314-24.
    View in: PubMed
    Score: 0.040
  152. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15; 22(12):1689-707; quiz 1837.
    View in: PubMed
    Score: 0.039
  153. Levodopa-induced dyskinesias. Mov Disord. 2007 Jul 30; 22(10):1379-1389.
    View in: PubMed
    Score: 0.039
  154. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol. 2007 May; 66(5):329-36.
    View in: PubMed
    Score: 0.038
  155. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol. 2007 Apr; 66(4):251-7.
    View in: PubMed
    Score: 0.038
  156. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol. 2007 Feb; 64(2):261-5.
    View in: PubMed
    Score: 0.037
  157. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 Dec; 21(12):2078-81.
    View in: PubMed
    Score: 0.037
  158. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6.
    View in: PubMed
    Score: 0.035
  159. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006 Jan 10; 66(1):93-8.
    View in: PubMed
    Score: 0.035
  160. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005 Feb; 20(2):130-40.
    View in: PubMed
    Score: 0.033
  161. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
    View in: PubMed
    Score: 0.033
  162. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
    View in: PubMed
    Score: 0.032
  163. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.031
  164. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol. 2004 Mar-Apr; 27(2):58-62.
    View in: PubMed
    Score: 0.031
  165. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.030
  166. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.030
  167. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.029
  168. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol. 2003 May; 53(5):624-9.
    View in: PubMed
    Score: 0.029
  169. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003 Apr; 72(4):804-11.
    View in: PubMed
    Score: 0.028
  170. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002 May 04; 359(9317):1589-98.
    View in: PubMed
    Score: 0.027
  171. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
    View in: PubMed
    Score: 0.027
  172. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1591-601.
    View in: PubMed
    Score: 0.017
  173. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1600-11.
    View in: PubMed
    Score: 0.017
  174. A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord. 2014 May; 29(6):743-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.